目的 评估长周期应用重组人血管内皮抑制素(恩度)联合激素及放疗治疗晚期前列腺癌的临床疗效及不良反应。方法 分析了28例经组织学确诊符合入组条件的晚期前列腺癌患者，分成实验组和对照组，实验组18例，对照组10例，实验组采用恩度联合同步激素治疗及放疗，对照组采用激素治疗及放疗，观察两组的疗效及不良反应。结果 ① 在不同治疗、不同时间中，实验组及对照组治疗前后FPSA、TPSA均降低，P<0.01，提示两种治疗对前列腺癌均有效；② 实验组及对照组FPSA及TPSA均在前两月降低幅度较大，并同其后各月份比较均有统计学意义，P均＜0.01；实验组在不同时间FPSA、TPSA水平均低于对照组，P均＜0.01，提示联合恩度优于只用激素治疗及放疗；③ 骨髓抑制程度实验组明显高于对照组，以白细胞降低为著，差异有统计学意义（Z=3.099，P=0.002）。结论 联合恩度治疗前列腺癌优于只用激素治疗及放疗，表现为FPSA、TPSA下降幅度迅速，维持水平较低、持续时间较长。

Objective To evaluate the clinical efficacy and adverse reactions for long-term application of recombinant human endostatin with concurrent hormone and radiation therapy for advanced prostate cancer. Methods 28 patients with histologically confirmed advanced prostate cancer were divided into experimental (18 patients) and control groups (10 patients). The experimental group was treated with endostatin combined with concurrent hormone and radiation therapy, and the control group was treated with hormones and radiotherapy. The efficacy and adverse reactions for both groups were observed. Results The serum levels of PSA and TPSA in experimental group and control group after treatment were lower than that of pretreatment (P <0.01), This indicated that two treatments were effective for prostate cancer. The serum levels of FPSA and TPSA in both experimental group and control group were decreased by a big margin in two months after treatment (P <0.01). The serum levels of FPSA and TPSA in experimental group at different times were lower than that of control group (P <0.01). The bone marrow suppression in experimental group mainly in white blood cells as the most important was significantly higher than that of control group (P<0.05). Conclusion The combined Endostatin with hormone and radiotherapy for prostate cancer treatment are superior to single treatment. The serum levels of FPSA and TPSA decline rapidly and maintaining a lower level for longer duration.